Tdp-43 cryptic exons are highly variable between cell types
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Yun Ha | - |
dc.contributor.author | Ling, Jonathan P. | - |
dc.contributor.author | Lin, Sophie Z. | - |
dc.contributor.author | Donde, Aneesh N. | - |
dc.contributor.author | Braunstein, Kerstin E. | - |
dc.contributor.author | Majounie, Elisa | - |
dc.contributor.author | Traynor, Bryan J. | - |
dc.contributor.author | LaClair, Katherine D. | - |
dc.contributor.author | Lloyd, Thomas E. | - |
dc.contributor.author | Wong, Philip C. | - |
dc.date.accessioned | 2023-08-16T09:51:22Z | - |
dc.date.available | 2023-08-16T09:51:22Z | - |
dc.date.created | 2022-01-13 | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 1750-1326 | - |
dc.identifier.uri | http://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/833 | - |
dc.description.abstract | Background: TDP-43 proteinopathy is a prominent pathological feature that occurs in a number of human diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myositis (IBM). Our recent finding that TDP-43 represses nonconserved cryptic exons led us to ask whether cell type-specific cryptic exons could exist to impact unique molecular pathways in brain or muscle. Methods: In the present work, we investigated TDP-43's function in various mouse tissues to model disease pathogenesis. We generated mice to conditionally delete TDP-43 in excitatory neurons or skeletal myocytes and identified the cell type-specific cryptic exons associated with TDP-43 loss of function. Results: Comparative analysis of nonconserved cryptic exons in various mouse cell types revealed that only some cryptic exons were common amongst stem cells, neurons, and myocytes; the majority of these nonconserved cryptic exons were cell type-specific. Conclusions: Our results suggest that in human disease, TDP-43 loss of function may impair cell type-specific pathways. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Tdp-43 cryptic exons are highly variable between cell types | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeong, Yun Ha | - |
dc.identifier.doi | 10.1186/s13024-016-0144-x | - |
dc.identifier.scopusid | 2-s2.0-85011304395 | - |
dc.identifier.wosid | 000396291900001 | - |
dc.identifier.bibliographicCitation | MOLECULAR NEURODEGENERATION, v.12 | - |
dc.relation.isPartOf | MOLECULAR NEURODEGENERATION | - |
dc.citation.title | MOLECULAR NEURODEGENERATION | - |
dc.citation.volume | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | AMYOTROPHIC-LATERAL-SCLEROSIS | - |
dc.subject.keywordPlus | FRONTOTEMPORAL LOBAR DEGENERATION | - |
dc.subject.keywordPlus | INCLUSION-BODY MYOSITIS | - |
dc.subject.keywordPlus | HEXANUCLEOTIDE REPEAT | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.subject.keywordPlus | ALS-FTD | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | RNA | - |
dc.subject.keywordPlus | DEPLETION | - |
dc.subject.keywordPlus | DEMENTIA | - |
dc.subject.keywordAuthor | TDP-43-Nonconserved cryptic exons | - |
dc.subject.keywordAuthor | Bioinformatics | - |
dc.subject.keywordAuthor | Amyotrophic lateral sclerosis | - |
dc.subject.keywordAuthor | Frontotemporal dementia | - |
dc.subject.keywordAuthor | Inclusion body myositis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
61, Cheomdan-ro, Dong-gu, Daegu, Republic of Korea , 41062 053-980-8114
COPYRIGHT Korea Brain Research Institute. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.